Summary
Overview
Work History
Education
Skills
Board Certification
Summary Of Experience
Publications
Writing (fiction and poetry), swimming
Timeline
Generic

Adelekan (Lekan) Oyejide

Raleigh,NC

Summary

Performance-driven executive director of pathology with a forward-thinking approach to achieving corporate success and driving competitive growth. Demonstrated track record of over 11 years in building a highly respected pathology organization at Regeneron. Proven expertise in pathology recruiting and retention, strategic planning, financial management, team development, and cross-functional collaboration across therapeutic areas. Adept at identifying opportunities and implementing practical business strategies while staying informed about the latest trends, technologies, and best practices in the field.

Overview

22
22
years of professional experience

Work History

Executive Director, Pathology

Regeneron Pharmaceuticals, Inc.
01.2016 - 12.2023
  • Worked with SVP and other senior DSP line management to align department vision, goals, and objectives with company strategy.
  • Supervised CRO Pathology collaboration on GLP Toxicology studies
  • Provided oversight for both Discovery (Investigative Pathology) and GLP Toxicology (Regulatory Pathology) work load. Supervised 11 direct reports, including 7 DVM PhD and 2 MD PhD Pathologists and two PhD scientist laboratory managers
  • Leveraged technology to automate workflows and streamline processes, through implementation of a robust Digital Pathology platform powered by Aperio scanners, eSlide Manager and HALO Image analysis software
  • Reviewed and approved Pathology portions of toxicology documents as part of regulatory document submission process to FDA/EMA and others
  • Streamlined Pathology Operations strategy to respond the translational pathology needs of Clinical HistoCore, Precision Medicine and Regeneron Genetics Center
  • Board member, Preclinical and Clinical Histology Cores
  • Collaborated with Regulatory Affairs colleagues to determine issues that might require pre-IND meetings with Regulatory Agencies
  • Managed on-going Pathology support for Regeneron’s marketed drugs, including aflibercept, alirocumab, dupilumab, sarilumab, cemiplimab and pozelimab.
  • Negotiated contracts with CRO vendors, securing favorable terms while adhering to budgetary constraints.
  • Built and maintained strong Pathology teams by hiring and training qualified staff to create positive and productive work environments.
  • Presented regularly at internal and external Pathology conferences and symposia showcasing the accomplishments of the organization.
  • Facilitated successful FDA inspections of Pathology facilities and functions, ensuring compliance with GLP regulations.
  • Led cross-functional teams for the successful completion of major projects, resulting in increased efficiency and Project Team satisfaction.
  • Implemented a rigorous histopathology peer review system of internal and external toxicology studies using both manual and digital tools to drive data-driven diagnostic decision-making, leading to improved safety risk assessment for Regeneron drug candidates.
  • Ensured regulatory compliance at all times by implementing robust internal controls systems coupled with proactive monitoring mechanisms.
  • Managed financial, operational and human resources to optimize Pathology Department business performance.

Director and Head, Pathology/DSP

Regeneron Pharmaceuticals, Inc.
02.2012 - 12.2015
  • Established in-house Pathology capabilities at Regeneron (2012)
  • Hired and oversaw the work/performance/development of 5 Pathologist direct reports; grew Pathology operations into a major preclinical functional area within 3 years
  • Provided primary pathology evaluation support for the BLA submission of several drug candidates that eventually obtained regulatory approval, including: Praluent (alirocumab), Dupixent (dupilumab) and Libtayo (cemiplimab)
  • Provided pathology peer review of 189 GLP toxicology and investigative pathology studies
  • Strategically managed Pathology team contributions in Discovery to support target validation and drug candidate selection
  • Resolved specific, unusual immunopathology or toxicology-related problems or issues
  • Anticipated future toxicology/pathology research needs and initiated the development and implementation of new approaches
  • With VP, DSP, participated in corporate strategy development and advocacy for Toxicology
  • Ensured that the pathology components of toxicology programs were GLP compliant
  • Along with leaders of other preclinical disciplines, worked with Regulatory Affairs to identify issues that might require pre-IND meetings with Regulatory authorities for resolution.

Principal Research Pathologist

MERCK & Co.
05.2009 - 01.2012
  • Served as compound leader (CL) on two Biologics Development Programs
  • Participated in multidisciplinary collaborative efforts across Merck Research Laboratories
  • Contributed primary pathology evaluation support for 39 investigative, regulatory and GLP Pathology studies
  • Served as Pathology resource person on project teams
  • Was accountable for scientific oversight and mentoring of technical staff in the immunohistochemistry laboratory
  • Participated/presented at biweekly global pathology conferences and at national meetings
  • Pursued continuing education by benchmarking industry best practices in Toxicologic Pathology and Molecular Pathology
  • Assisted Senior Director and Global Head of Pathology with fiduciary, manpower and capital expenditure planning
  • Authored, reviewed and submitted pathology data and reports of preclinical safety studies
  • Provided high quality and timely Pathology reports on 43 GLP studies.
  • Enhanced diagnostic accuracy by conducting comprehensive histopathological examinations of tissue samples.
  • Mentored junior pathologists and lab technicians, fostering professional growth and skill development within the team.
  • Utilized histology, cytology, immunology, and other techniques on daily basis.
  • Evaluated and validated new laboratory equipment, ensuring the adoption of cutting-edge tools that improved diagnostic capabilities.

Pathologist, Scientific Director

Allergan Inc.
07.2001 - 02.2009
  • Served as primary project pathologist on the following approved Allergan drugs: Botox, Brimonidine, Restasis, Lumigan and intravitreal drug implants
  • Group leader, Boston Consulting Group Project to streamline DSE
  • Assisted Sr Director to execute short and long-term visions for the Pathology department
  • Provided primary anatomic and clinical pathology evaluation support for 135 preclinical GLP and non-GLP safety studies, including studies used to support the approval of marketed drugs: Lumigan, Lumilash, Restasis, Botox, Refresh Tears and Ozurdex
  • Served as Key User/Trainer for the Provantis LIMS
  • Provided oversight for CRO necropsy studies to ensure adherence to GLP regulations
  • Supervised Allergan’s Necropsy Group for seven years while managing 2 scientists and 4 technician direct reports
  • Manager, Immunohistochemistry Unit (9/2001 – 2/2002, 7/2006 – 6/2008)
  • Direct reports: 1 MS/PhD Scientist, 1 technician (Biologist)
  • Leader, Ocular Inflammation Program (6/2008 – 2/2009).
  • Evaluated and validated new laboratory equipment, ensuring the adoption of cutting-edge tools that improved diagnostic capabilities.

Education

Ph.D., Comparative Pathology -

University of California
Davis, CA

MS, Comparative Pathology (Immunopathology) -

University of California
Davis, CA

MPVM, Epidemiology -

University of California
Davis, CA

Doctor of Veterinary Medicine (DVM) -

University of Ibadan
Ibadan, Nigeria

Skills

  • Strategic Planning
  • Analytical and Critical Thinker
  • Executive Leadership
  • Effective Communicator and Public Speaker
  • Cross-Functional Collaboration
  • Innovative and Visionary
  • Industry Expertise
  • Decision-Making
  • Coaching and Mentoring
  • Complex Problem-Solving
  • Risk Management
  • Negotiation and Persuasion
  • Budget Oversight
  • Industry Best Practices
  • Company guidelines
  • Resource Allocation
  • Staff Recruiting and Retainment
  • Policy Development
  • Project Management
  • Results-Driven

Board Certification

American College of Veterinary Pathologists (DACVP)

Summary Of Experience

Board Certified Veterinary Anatomic Pathologist with 23 years of experience, focused on providing regulatory toxicologic pathology expertise in drug discovery and development.

Publications

  • Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice, Jie Gao, Shumei Ren, Adelekan Oyejide, et al., Disease Models and Mechanisms, 16(10), 2023
  • Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models, Audrey Le Floc'h, Kirsten Nagashima, Adelekan Oyejide, et al., Science Translational Medicine, 15(678), 2023
  • IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline, George Scott, Seblewongel Asrat, Adelekan Oyejide, et al., Cytokine, 162(1), 2023
  • The Activin/FLRG pathway associates with poor COVID-19 outcomes in hospitalized patients, Megan McAleavy, Qian Zhang, Adelekan Oyejide, et al., Molecular and Cellular Biology, 42(1), 2022
  • Comparison of transcriptional differences between IL-4Ra and IL-5 blockade in a mouse model of asthma, George Scott, Jeanne Allinne, Adelekan Oyejide, et al., European Respiratory Journal, 58(PA674), 2021
  • Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets, Dhiraj Kumar Singh, Bindu Singh, Adelekan Oyejide, et al., Nature Microbiology, 6(3), 2021
  • REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, Alina Baum, Dharani Ajithdoss, Adelekan Oyejide, et al., Nat Microbiol, 6(3), 2020
  • SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species, Dhiraj Kumar Singh, Shashank R. Ganatra, Adelekan Oyejide, et al., bioRxiv, 05 Jun 2020
  • Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine, Zaruhi Hovhannisyan, Nengyin Liu, Adelekan Oyejide, et al., Science Immunology, 5(54), 2020
  • A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies, Lauric Haber, Dimitris Skokos, Adelekan Oyejide, et al., Science Translational Medicine, 12(525), 2020

Writing (fiction and poetry), swimming

I have written radio plays, published short stories and I am working on a novel

Timeline

Executive Director, Pathology

Regeneron Pharmaceuticals, Inc.
01.2016 - 12.2023

Director and Head, Pathology/DSP

Regeneron Pharmaceuticals, Inc.
02.2012 - 12.2015

Principal Research Pathologist

MERCK & Co.
05.2009 - 01.2012

Pathologist, Scientific Director

Allergan Inc.
07.2001 - 02.2009

Ph.D., Comparative Pathology -

University of California

MS, Comparative Pathology (Immunopathology) -

University of California

MPVM, Epidemiology -

University of California

Doctor of Veterinary Medicine (DVM) -

University of Ibadan

Similar Profiles

  • Momodou W. Jallow

    Momodou W. JallowMomodou W. Jallow

    Postdoctoral Fellow at Regeneron Genetic Center, Regeneron Pharmaceuticals, Inc.Postdoctoral Fellow at Regeneron Genetic Center, Regeneron Pharmaceuticals, Inc.

  • Marina Maiuri

    Marina MaiuriMarina Maiuri

    Associate Manager, VelociGene Operations at Regeneron Pharmaceuticals, Inc.Associate Manager, VelociGene Operations at Regeneron Pharmaceuticals, Inc.

  • Nicholas Moore

    Nicholas MooreNicholas Moore

    Clinical Study Specialist, Clinical Trial Management at Regeneron Pharmaceuticals, Inc.Clinical Study Specialist, Clinical Trial Management at Regeneron Pharmaceuticals, Inc.

  • Rebecca Nash

    Rebecca NashRebecca Nash

    Training Coordinator at Regeneron Pharmaceuticals, Inc.Training Coordinator at Regeneron Pharmaceuticals, Inc.

  • Latoya Taylor

    Latoya TaylorLatoya Taylor

    Health Insurance Financial Advisor at Sutherland / Horizon BCBSHealth Insurance Financial Advisor at Sutherland / Horizon BCBS

CREATE PROFILE
Adelekan (Lekan) Oyejide